Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

NCT02474173 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

31

Enrollment

NIH

Sponsor class

Stopped Drug supply issues

Conditions

Advanced Breast Carcinoma
Metastatic Breast Carcinoma
Stage III Breast Cancer AJCC v7
Stage IIIA Breast Cancer AJCC v7
Stage IIIB Breast Cancer AJCC v7
Stage IIIC Breast Cancer AJCC v7
Stage IV Breast Cancer AJCC v6 and v7
Triple-Negative Breast Carcinoma

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Onalespib
DRUG: Paclitaxel
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)